Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRX-2843 in relapsed/refractory advanced and/or metastatic solid tumors
NCT03510104Phase 1Completed
- Sponsor
- Meryx, Inc.
- Start
- May 2018
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MRX-2843 in cancer and metastatic cancer, sponsored by Meryx, Inc. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events and Serious Adverse Events at 12 months. Started May 2018; status: completed.
02
Drugs
MRX-2843
03
Conditions
cancermetastatic cancer
Beyond the preview
Go deeper on NCT03510104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510104.